



MedImmune

Particle Design via Spray Drying

Reinhard Vehring

MedImmune Inc., 319 North Bernardo Ave, Mountain View, CA 94043


David Lechuga-Ballesteros

Nektar Therapeutics, 150 Industrial Rd., San Carlos, CA 94002

Outline

- **Study of Particle Formation Mechanism**
 - Experimental Methods
 - Droplet Chain
 - Monodisperse Spray Dryer
 - Theoretical Approach
 - Results
- **Particle Design Examples**
- **Summary and Outlook**


Droplet Chain Technique



- Droplets do not influence gas phase
- Allows measurement of evaporation rates


Monodisperse, Monomorph Particles

Production Lot




Geometric diameter and density can be correlated with drying rate
Only small quantities can be produced (< 1mg/h)

Monodisperse Spray Dryer




- 1000 x higher production rates
- Gas phase conditions not constant
- No direct observation of evaporation process
- Online measurement of aerodynamic dry particle diameter

Particles from Monodisperse Spray Dryer



- Consistent morphology
- Density of main population can be determined

Numerical Model of Droplet Evaporation



- Transient evaporation of a radially symmetric droplet
- Finite difference mesh moves with interface
- Concentration and temperature profiles in liquid and gas
- Temperature and concentration dependent material properties
- Multiple solutes and solvents
- Accounts for surface activity

Analytical Description

Analytical model provides dimensionless numbers

Diffusion equation for normalized radial coordinate, $R=r/r_s$,

$$\frac{\partial c}{\partial t} = \frac{D}{r_s^2} \left(\frac{\partial^2 c}{\partial R^2} + \frac{2\partial c}{R\partial R} \right) + \frac{R\partial c\partial r_s}{r_s\partial R\partial t}, \quad d^2(t) = d_0^2 - \kappa t$$


D : Diffusion coefficient, c : concentration, r_s : droplet radius, d : droplet diameter, κ : evaporation rate.

Solution

$$c = c_m \frac{\exp(-0.5\text{Pe}R^2)}{3 \int_0^1 R^2 \exp(-0.5\text{Pe}R^2) dR}, \quad \text{Pe} = -\frac{r_s \partial r_s}{D \partial t} = \frac{\kappa}{8D}$$

where the concentration is expressed as a function of the average concentration in the droplet, c_m . Pe is the Peclet number.


Case 1: Large Molecules




Morphology and density change with drying rate

Glycoprotein, MW: 51 kDa, D: $6 \cdot 10^{-11}$ m²/s (estimate)

Density Decreases with Increasing Pe-Number




Model Predicts Surface Enrichment of Protein




Glycoprotein, T_G : 25 °C

Comparison with Experiment Verifies Mechanism




Dry particle formation coincides with predicted high surface concentration of the protein.



Diffusion Controlled Particle Formation



Buckling of Shells Made of Nanoparticles




- Millimeter sized droplet levitated by Leidenfrost phenomenon
- 2 mg/ml polystyrene nanoparticle (170 nm) suspension



Courtesy of Nicolas Tsapis
Faculté de Pharmacie
Châtenay-Malabry

Tsapis et al. PRL 94, 018302 (2005);
Sugiyama et al. Langmuir, 22, 6024 (2006)


Case 2: Small Molecules




Low Peclet Number (<2) and high solubility leads to solid particles with a density close to the pycnometer density (1.53 g/cm³)

Small Molecules

Low Solubility – High Surface Activity



Solubility: 8 mg/ml (25°C, pH7)
Surface Activity: 42 mN/m (sat, 25°C)
MW: 357.5 Da





Particles with very low density can be formed from small molecules

Small Molecules


Low Solubility – Low Surface Activity

Pe ~ 0.9




Surface activity is not necessary for low particle density

Particle Formation Coincides with Supersaturation




Precipitation leads to sharp increase in Pe - number

Particle Formation with Early Phase Separation



Designing Structured Particles - Applications




- Encapsulation
- Structural layers


- Improving physical stability
- Improving biological / chemical stability
- Improving powder / aerosol properties
 - Flowability
 - Dispersibility
 - Density / Aerodynamic diameter
- Improving delivery
 - Solubility
 - Bioadhesion
 - Release

Encapsulation of a Model Molecule

100 % PVP K17




90 % PVP, 10 % Amino Acid




Amino acid solubility intentionally reduced by a co-solvent to achieve encapsulation

Surface Modification of an Antibody Therapeutic

IgG1 - Antibody






Encapsulated
with 37.5 % amino acid



Encapsulation Improves Aerosol Performance


Gentamicin Sulfate

Netilmicin Sulfate




Encapsulation Improves Physical Stability


56 % encapsulation excipient, 20 % saccharide, 20 % low Tg API, 4 % organic salt



Low Tg core protected
by a high Tg shell



Structured Particle with Excellent Environmental Robustness



~ 20 °C above Tg !

Summary and Outlook

- Particle formation can be understood in the context of component saturation and Peclet number
- Surface activity and other material properties may influence particle morphology
- Analysis of particle formation enables rational particle design of structured particles through formulation and process design
- Particle engineering achieves much improved particle properties, enabling new products and improving product performance
- More work is necessary to understand and control nanostructures and multiple functional layers
- Process technology and formulation science must work together

Acknowledgements

Willard R. Foss

Amgen Inc., Thousand Oaks, CA

Christopher I. Grainger

Kings College, London

Mei Chang Kuo, Danforth P. Miller

Nektar Therapeutics, San Carlos, CA

Solid State Formulation Group

MedImmune Inc., Mountain View, CA

**James Ivey, Lisa Williams, Sandhya Buchanan, Yi Ao,
Luisa Yee, Emilie Pan, Rekha Rao**